We provide the proof to improve healthcare decisions
Irvine, CA (PRWEB) April 16, 2015
Proove Biosciences, Inc. is pleased to participate in the Buzz of BIO Contest for the 2015 BIO International Convention. Hosted by the Biotechnology Industry Organization (BIO), the 2015 BIO International Convention will take place June 15-18 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania. During the Buzz of BIO contest, industry leaders will be voting for companies they would like to see present at the conference. The community voting period began on April 14, 2015 and ends at 5:00:00 PM ET on April 21, 2015 at: http://convention.bio.org/buzzofbio/ Proove has been nominated in the Technologies of Tomorrow category.
“To be nominated in the Buzz of BIO Contest is such an honorable recognition.” states Brian Meshkin, Proove Founder & CEO. “We provide the proof to improve healthcare decisions. Unlike the hundreds of companies out there providing what they call ‘pharmacogenetic’ testing, Proove has proprietary tests that are actually linked to outcomes. Our one-of-a kind testing brings rationale objective information to assessing and treating pain - the nation’s most expensive healthcare condition and the number one reason why people go to their primary care doctor. With our huge research database over 75,000 subjects and increasing every month, we have been able to bring to market unique personalized medicine testing and our proud to continue to win awards for our research.”
Proove is a leader in innovation addressing some of society’s largest problems with a menu of proprietary genetic tests. Here are just two examples:
Proove Opioid Risk TM - Helping Solve the Epidemic of Prescription Opioid Abuse with 93% Accuracy and a 3:1 Cost-Benefit to the Healthcare System
With prescription medication abuse now becoming the largest cause of teenage death in the U.S. and with 3 times as many people addicted to and dying from prescription narcotics than all of the illegal narcotics combined, the Proove Opioid RiskTM profile is the world’s only test to identify a patient at risk for the misuse or abuse of opioids, a test that in head-to-head studies has been found to more accurate than leading conventional survey tools.
Proove Pain Perception - Objectively Stratifying Patient Perception to Rationally Guide Patient Care with a 2:1 Cost-Benefit to the Healthcare System
Proove Pain Perception is the world’s only test to objectively assess a patient’s perception. With data published in marquee journals such as Pain, Science, Nature, Human Molecular Genetics, and others, the Proove Pain Perception test helps clinicians interpret a patient’s numerical rating scale to better recommend treatment, further diagnostics, or candidates for surgery.
About Proove Biosciences
Our Mission is to Change the Future of Medicine. Proove is the proof to improve healthcare decisions. We seek to realize a future when clinicians look back and wonder how they could’ve ever prescribed medications without knowing how a patient would respond. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of personalized pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve outcomes – both safety and efficacy of medical treatment. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).
ABOUT THE BIO INTERNATIONAL CONVENTION
The annual BIO International Convention is the largest global event for the biotechnology industry. The Convention attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry.